2. Search Result
Search Result
Results for "

gastric mucosa

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Peptides

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0261
    Pentagastrin
    1 Publications Verification

    ICI-50123

    		 Cholecystokinin Receptor Endocrinology Cancer
    Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury . .
    Pentagastrin
  • HY-A0261A
    Pentagastrin meglumine

    ICI-50123 meglumine

    		 Cholecystokinin Receptor Endocrinology Cancer
    Pentagastrin (ICI-50123) meglumine is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin meglumine enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury . .
    Pentagastrin meglumine
  • HY-129471
    Arbaprostil

    		Endogenous Metabolite Inflammation/Immunology
    Arbaprostil is an orally active PGE1 (HY-B0131) analog. Arbaprostil protects the gastrointestinal mucosa from stomach acid and other irritants, promotes healing rate of gastric ucler through the antisecretory effect .
    Arbaprostil
  • HY-106449
    Recoflavone

    DA-6034 free acid

    		 Others Inflammation/Immunology Cancer
    Recoflavone is a synthetic derivative of eupatilin that has a protective effect on gastric mucosa. Recoflavone has the potential to be used to research peptic ulcer disease.
    Recoflavone
  • HY-137273
    Sucrose octasulfate sodium

    		Others Others
    Sucrose octasulfate is a component of sulfoaluminum. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin Sucrose octasulfate can be used for anti-gastric ulcer research .
    Sucrose octasulfate sodium
  • HY-15035
    S-Diclofenac

    ACS 15; ATB-337

    		 COX Inflammation/Immunology
    S-Diclofenac is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac spares the gastric mucosa of injury despite markedly suppressing prostaglandin synthesis .
    S-Diclofenac
  • HY-B0360
    Rebamipide
    3 Publications Verification

    OPC12759; Proamipide

    		 COX Inflammation/Immunology Cancer
    Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .
    Rebamipide
  • HY-W003445
    4-Bromo-3-hydroxybenzoic acid

    		Endogenous Metabolite Neurological Disease
    4-Bromo-3-hydroxybenzoic acid is a metabolite of Brocresine and a histidine decarboxylase (HDC) inhibitor with IC50s of 1 mM for both rat fetal and rat gastric HDC. 4-Bromo-3-hydroxybenzoic acid also inhibits aromatic-L-amino acid decarboxylase from hog kidney and rat gastric mucosa in vitro with IC50s of 1 mM for both enzymes .
    4-Bromo-3-hydroxybenzoic acid
  • HY-B1330
    Proglumide

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide
  • HY-103354
    Proglumide sodium

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium
  • HY-103354A
    Proglumide hemicalcium

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
    Proglumide hemicalcium
  • HY-111313
    JNJ-26070109

    		Cholecystokinin Receptor Metabolic Disease
    JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .
    JNJ-26070109

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: